(IC50 = 31 ± 2 nM) and a moderately selective eqBuChE inhibitor (IC50 = 4.7 ± 0.2 μM). Conversely, the new and readily available 5-amino-7-(prop-2-yn-1-yl)-6,7,8,9-tetrahydropyrido[2,3-b][1,6]naphthyridine derivatives 9–13 of type II are poor MAO inhibitors, but showed AChE selective inhibition, compound 12 being the most attractive as it acts as a non-competitive inhibitor on EeAChE (IC50 = 25 ± 3 nM, Ki = 65 nM)
合成,药理学评估和分子建模杂环取代的烷基和环烷基
炔丙基胺1 - 7型的我,和9 - 12型的II,设计为多能的
抑制剂能够同时抑制单胺氧化酶(MAO-A / B),以及描述了作为
胆碱酯酶(AChE / BuChE)的酶,作为治疗阿尔茨海默氏病的潜在药物。
吲哚衍
生物1 - 7型的我是公知的MAO
抑制剂,其容量,以抑制
乙酰胆碱酯酶和丁酰
胆碱酯酶在这里研究首次。结果,化合物7被鉴定为MAO-B
抑制剂(IC 50 = 31±2 nM)和中等选择性eqBuChE
抑制剂(IC 50 = 4.7±0.2μM)。相反,新的和容易获得的5-
氨基-7-(prop-2-yn-1-yl)-6,7,8,9-四氢
吡啶并[2,3- b ] [1,6]
萘啶衍
生物9 – II型中的13种是较弱的MAO
抑制剂,但表现出AChE选择性抑制作用,化合物12最有吸引力,因为它作为Ee AChE的非竞争性
抑制剂起作用(IC 50 =